Isamu Sugiura

High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed <i>BCR</i>-<i>ABL</i>–Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group

Masamitsu Yanada, Jin Takeuchi, Isamu Sugiura et al. · Journal of Clinical Oncology · 2005 · 452 citations · Full text

Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study

Shigeru Kusumoto, Yasuhito Tanaka, Ritsuro Suzuki et al. · Clinical Infectious Diseases · 2015 · 147 citations · Full text

Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11

Yuichi Ishikawa, Naomi Kawashima, Yoshiko Atsuta et al. · Blood Advances · 2020 · 117 citations · Full text

Prospective monitoring of <i>BCR‐ABL1</i> transcript levels in patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia undergoing imatinib‐combined chemotherapy

Masamitsu Yanada, Isamu Sugiura, Jin Takeuchi et al. · British Journal of Haematology · 2008 · 101 citations · Full text

Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy

Masamitsu Yanada, J. Takeuchi, Isamu Sugiura et al. · Haematologica · 2008 · 62 citations · Full text

Karyotype Imaging, Hematological Malignancy, Health Sciences +14